Condensed heterocyclic compounds

Abstract

FIELD: chemistry. SUBSTANCE: invention relates to novel compounds of formula (I) or pharmaceutically acceptable salts thereof, having CRP receptor antagonist activity. In formula (I) R 1 denotes C 3 -C 8 alkyl, optionally substituted with hydroxyl; phenyl optionally substituted with 1-3 substitutes selected from halogen, nitro, amino, hydroxyl, C 1 -C 4 alkoxy, C 1 -C 4 alkyl, optionally substituted with hydroxyl or C 1 -C 4 alkylamino; naphthyl; C-bonded 5-6-member heteroaryl with 1-2 heteroatoms selected from S, N or O, optionally substituted with C 1 -C 4 alkyl, C 1 -C 4 alkoxy or acetyl; N-bonded 5-member heteroaryl with 1-2 heteroatoms selected from N, optionally substituted with 1-3 substitutes selected from C 1 -C 4 alkyl or phenyl; R 2 denotes phenyl, optionally substituted with 1-3 substitutes selected from C 1 -C 4 alkyl, halogenC 1 -C 4 alkyl, C 1 -C 4 alkoxy, halogenC 1 -C 4 alkoxy, halogen, hydroxy, di(C 1 -C 4 alkyl)amino or di(C 1 -C 4 alkyl)aminocarbonyl; or a heterocyclic group which is pyridyl, optionally substituted with 1-3 substitutes selected from C 1 -C 4 alkyl, C 1 -C 4 alkoxy or di(C 1 -C 4 alkyl)amino; X denotes -NR 3 -, where R 3 denotes C 1 -C 4 alkyl, optionally substituted with hydroxyl, carboxyl or C 1 -C 4 alkoxycarbonyl; Y 1 denotes CR 3a , where R 3a denotes hydrogen, halogen, cyano, hydroxy, C 1 -C 4 alkyl, optionally substituted with hydroxyl or halogen, C 1 -C 4 alkoxy optionally substituted with halogen; Y 2 denotes CR 3b , where R 3b denotes hydrogen or halogen; Y 3 denotes N or CR 3c , where R 3c denotes hydrogen; and Z denotes O or -NR 4 -, where R 4 denotes hydrogen. EFFECT: invention also pertains to a method of producing compounds of formula (I), a pharmaceutical composition, an inhibiting method, CRF receptor antagonists and use thereof to prepare a medicinal agent. 25 cl, 9 tbl, 163 ex